Abstract
We demonstrate that during 23A2 skeletal myoblast differentiation, between 30–35% of the population apoptose. Both differentiation and apoptosis are controlled by the variables of cell density and time and these variables are inversely related. In response to conditions that permit both differentiation and apoptosis of parental 23A2 myoblasts, myoblasts rendered differentiation-defective by constitutive Ras signaling (A2:H-Ras myoblasts) do not apoptose. This is not merely a consequence of their differentiation-defective phenotype since myoblasts rendered differentiation-defective by expression of E1A (A2:E1A myoblasts) still apoptose. Although signaling through MEK is important to the survival of proliferating parental 23A2 myoblasts, constitutive signaling through MEK is not responsible for the survival of A2:H-Ras myoblasts. Finally, we demonstrate that caspase 3 is activated and that pharmacological inhibition of caspase 3 activity delays apoptosis without affecting differentiation. Abrogating apoptosis without affecting differentiation could be a useful approach to improve the efficacy of myoblast transfer in the treatment of muscular dystrophies.
Similar content being viewed by others
Introduction
Apoptosis occurs in all tissues and is as critical to normal development and homeostasis as proliferation, migration and differentiation.1,2 As testament to the vital importance of apoptosis, inappropriate apoptosis is associated with many pathological conditions.3 Like the apoptosis of thymocytes and neurons,1,2 the apoptosis of myoblasts is a physiological process during myogenesis4 and regeneration and likely serves the critical function of removing excess myoblasts.5 During the process of differentiation, apoptosis has been documented in cultures of primary myoblasts6 and in established muscle cell lines.7 Inappropriate myoblast apoptosis contributes pathologically to the degeneration associated with various muscular dystrophies8,9 and spinal muscular atrophies.10,11 Furthermore, despite great advances in vector design and protocols which decrease immune responses,12,13 myoblast therapy as an approach to the treatment of inherited muscular dystrophies is still severely impaired by the poor survival of transplanted myoblasts.14,15
The therapeutic manipulation of myoblasts can be facilitated through a complete molecular understanding of their biology. The very idea that myoblast transfer is a conceptually viable approach to treat myopathies originated over 20 years ago from a fundamental understanding about how multinucleated skeletal muscle is formed.16 Since then, a combination of studies in cell lines and mice has delineated the specific roles of a family of muscle regulatory transcription factors (MRFs) composed of MyoD, Myogenin, Myf-5 and MRF4. Much is also known about the signaling pathways regulating the MRFs.17 Signaling by appropriate concentrations of IGFs through the PI3-kinase/Akt pathway18,19,20,21 is known to be required for differentiation while signaling by FGF-2 or high concentrations of IGF through the Raf/MEK pathway is known to inhibit differentiation.22 Despite the wealth of molecular knowledge about skeletal myoblast determination, proliferation, and differentiation, information regarding skeletal myoblast apoptosis is limited to a few reports that during the process of differentiation induced by culture in low serum containing medium, roughly 30% of myoblasts die via apoptosis.7 The ability to escape this apoptosis seems to be linked to cell cycle exit.7,23,24
The molecules responsible for the apoptotic process have not been examined in myoblasts but have been extensively studied in other systems. Apoptosis is tightly regulated by a continually emerging plethora of molecular checks and balances designed to control the activation of a family of cysteine, aspartic acid specific proteases (caspases). This complex array of regulatory molecules makes possible the distinct regulation of caspase activation in each system. Caspases naturally exist as procaspases which are themselves activated by limited proteolytic processing after aspartic acid. Procaspases are generally divided into two classes. ‘Initiator’ caspases like caspases 8 and 9 contain prodomains that permit aggregation in response to an apoptotic signal.25,26 Aggregation permits allosteric activation27 as well as activation as a consequence of trans- or self-processing. Activated initiator caspases then activate the ‘executioner’ caspases which include caspases 3, 6 and 7.28 Caspase activation via this cascade of limited proteolysis then results in the limited proteolysis of a discrete set of critical cellular proteins.25,26
To expand our extremely limited knowledge about the regulation of apoptosis that occurs during the differentiation of skeletal myoblasts, we carefully examined the conditions that result in the apoptosis of 23A2 skeletal myoblasts. We have documented that differentiation and apoptosis depend on the variables of cell density and time and that these variables are inversely related. We have determined that, under conditions that permit both differentiation and apoptosis of parental 23A2 myoblasts, constitutive signaling by Ras inhibits both their differentiation29 and their apoptosis while signaling by E1A inhibits only their differentiation. Thus, the inhibition of differentiation can be separated from the inhibition of apoptosis. We used PD098059, a selective pharmacological inhibitor of MEK, to show that while MEK signaling does play a role in the survival of 23A2 myoblasts under growth conditions, the Ras-induced inhibition of apoptosis under differentiation-inducing conditions is MEK independent. To investigate further the possible separation of signals required for differentiation from those signals required for apoptosis, we determined that pharmacological inhibition of caspase 3 signaling delays apoptosis without affecting differentiation. Inhibiting apoptosis without affecting differentiation could eventually be a viable approach to preventing the deterioration associated with many muscular dystrophies and could also improve the therapeutic efficacy of myoblast transfer.
Results
Differentiation and apoptosis are cell density and time dependent
Apoptosis has been documented in C2C12 myoblasts induced to differentiate by switching cultures from high serum growth medium to low serum differentiation medium.7 We too switched cultures from high serum growth medium (GM) to differentiation medium without serum (DM) to document the induction of both differentiation and apoptosis in 23A2 myoblasts and also extended these studies to document differentiation and apoptosis as a consequence of extended culture in GM. We chose to also perform these studies in GM as this is possibly more representative of the in vivo process. Furthermore, we analyzed the effect of varying cell density and time on differentiation and apoptosis for both approaches.
To monitor differentiation, we used myosin heavy chain (MHC) as our marker and documented its expression by both Western analysis (Figure 1A) of lysates and by immunostaining of cell cultures (Figure 1B,C). The Western analysis is quantitative with respect to the amount of MHC that is expressed while the immunostain is quantitative with respect to the percentage of cells that have initiated MHC expression. By plating cells at the same density and monitoring MHC expression over time in either DM or GM, we can document that differentiation is time dependent (Figure 1A, B). By plating cells at different densities and monitoring MHC expression after the same time in either DM or GM, we can also show that differentiation is density dependent (Figure 1C). It is clear from both analyses that these variables of time and density are inversely related. It is also clear that differentiation occurs faster when cells are switched from GM to DM than under extended culture in GM, for example, compare 24 h in DM to 24 h in GM (Figure 1A, B). The lag time between the differentiation that occurs under extended culture in GM and the differentiation that occurs when cells are switched from GM to DM is roughly 24 h (Figure 1C).
To monitor apoptosis, we used DNA fragmentation as our marker and documented it by both immunostaining of cell cultures (Figure 2) and ELISA of cytosolic lysates (Figure 3). The immunostain is quantitative with respect to the percentage of cells that have initiated apoptosis and takes into account both cells that remain on the plate and those that have fallen off of the plate after completing the process of apoptosis. By plating cells at the same density and monitoring DNA fragmentation over time in either DM (Figure 2A) or GM (Figure 2B), we can document that apoptosis is time dependent. By plating cells at different densities and monitoring DNA fragmentation after the same time in either DM (Figure 2C, D) or GM (Figure 2E), we can also show that apoptosis is density dependent. It is clear from both analyses that these variables of time and density are inversely related and that maximally 30–33% of the culture apoptoses. Once again, it is also clear that apoptosis occurs faster when cells are switched from GM to DM than under extended culture in GM, for example, compare 24 h in DM to 24 h in GM (Figure 2A, B). The lag time between the apoptosis that occurs under extended culture in GM and the apoptosis that occurs when cells are switched from GM to DM is roughly 20 h (compare 4 h Figure 2A to 24 h Figure 2B). The lag time between the appearance of DNA fragmentation and detachment from the plate is less than 16 h in DM (Figure 2C, D) and greater than 24 h in GM (Figure 2B, compare 48 h to 72 h). We have also shown that the process of apoptosis, as monitored by DNA fragmentation and including detachment from the plate, can be completed much faster than the process of differentiation. This is most clearly observed by plating cells at 4×105 followed by culture for 24 h in DM prior to the detection of either differentiation (Figure 1A) or apoptosis (Figure 2D). Although the percentage of cells destined to apoptose is decided after 8 h in DM or 48 h in GM, these apoptotic cells have not yet detached from the plate under these conditions. This raises the possibility that the amount of MHC (since lysates are equalized for total cell protein) and the percentage of cells expressing MHC are slightly underestimated under conditions where apoptosis is not complete or is complete but the cells have yet to detach from the plate.
The ELISA analysis is quantitative with respect to the amount of cytosolic nucleosomes in cells remaining on the plate. Since after 8 h in DM most apoptotic cells are still attached to the plate (Figure 2C), this time point was chosen to demonstrate the density dependence of DNA fragmentation in either GM or DM (Figure 3A). To demonstrate that DNA fragmentation is also time dependent, myoblasts were plated at 5×104 and then cultured in either GM or DM for various times (Figure 3B). After 8 h in DM, the percentage of apoptotic cells correlates roughly with the amount of cytosolic nucleosomes (compare Figure 2C with Figure 3A). This is not true, however, as the process of apoptosis progresses over time. After 8 h, apoptotic cells equaling 4% (Figure 2C) of the population contain 40–45 absorbance units of cytosolic nucleosomes (Figure 3A, B) while after 24 h in DM apoptotic cells equaling 1% (Figure 2D) of the population contain 70 absorbance units of cytosolic nucleosomes (Figure 3B). Since the total cell number does not change between 8 and 24 h in DM, we can calculate that myoblasts after 24 h in DM contain almost ninefold more cytosolic nucleosomes than myoblasts after 8 h in DM. Nonetheless, it is again clear from both analyses that apoptosis occurs faster when cells are switched from GM to DM than under extended culture in GM and that apoptosis depends on the variables of cell density and time and that these variables are inversely related.
Abrogation of differentiation can be separated from abrogation of apoptosis
We have rigorously demonstrated that under various conditions of depleted growth factors some skeletal myoblasts differentiate while others apoptose. Even though initiated by the same stimulus of growth factor depletion, it is still possible that these processes can be separated. To examine this possibility, we measured apoptosis in two differentiation-defective myoblast cell lines. Myoblasts expressing constitutively active Ras (A2:H-Ras myoblasts) are differentiation-defective29,30 (Figure 4A) and apoptose at a level less than 1/10 that of the parental 23A2 myoblasts in either GM (Figure 4B) or DM (Figure 4B–D). In contrast, the apoptosis of myoblasts (A2:E1A) rendered differentiation-defective (Figure 4A) by expression of E1A31 is slightly elevated when compared to parental 23A2 myoblasts in either GM (Figure 4B) or DM (Figure 4B–D). The fact that A2:E1A myoblasts are differentiation-defective yet are not impaired in their ability to apoptose indicates that the positive effect of constitutively active Ras on myoblast survival is not merely a consequence of its negative effect on their differentiation.
Signaling by Ras through either the PI3-kinase/Akt pathway32 or the Raf/MEK/MAPK pathway has been implicated in cell survival.33 Since PI3 kinase/Akt signaling has been implicated in the normal survival/differentiation of skeletal myoblasts,20,21,23,24 we focused on the role of Raf/MEK signaling in the increased survival of A2:H-Ras myoblasts. We have previously reported that PD 098059, a selective MEK inhibitor, does not affect the differentiation of skeletal myoblasts.29 Furthermore, while PD 098059-induced abrogation of constitutive MEK signaling in A2:H-Ras myoblasts reverts their transformed phenotype, this does not revert their differentiation-defective phenotype.29 We have now determined that PD 098059-induced abrogation of constitutive MEK signaling (Figure 5A) does appear to increase the amount of DNA fragmentation in apoptotic A2:H-Ras myoblasts roughly 4–6-fold (Figure 5B). PD 098059 treatment, however, induces only a modest increase in the per cent of apoptotic A2:H-Ras myoblasts (Figure 5C). While constitutive MEK signaling may play a role in DNA fragmentation in apoptotic A2:H-Ras myoblasts, the role of constitutive MEK signaling in the overall survival of A2:H-Ras myoblasts is minimal. Even when cultured in DM plus PD 098059 where the greatest apoptosis of A2H-Ras myoblasts is observed, the per cent apoptotic A2:H-Ras myoblasts is less than 1/10 that of apoptotic 23A2 myoblasts cultured in DM without PD 098059 (Figure 5C).
The concentration of PD 098059 used to completely abrogate the constitutive MEK signal in A2:H-Ras myoblasts reduced the serum stimulated MEK signal by roughly 80% (data not shown). Interestingly, this reduction of the serum-stimulated MEK signal in 23A2 myoblasts caused the level of DNA fragmentation (Figure 5B) and the percentage of apoptotic cells (Figure 5C) to approach that observed when 23A2 myoblasts are cultured in DM. This suggests that serum-stimulated MEK signaling may play a critical role in myoblast survival in GM.
Abrogation of caspase 3 signaling delays apoptosis without affecting differentiation
Caspase 3, along with caspases 6 and 7, are considered to be the primary downstream caspases ultimately responsible for carrying out the process of apoptosis. Caspase 3-independent apoptosis, however, has been reported in several systems.34,35 Since no reports have yet examined the activation of caspases when skeletal myoblasts are induced to differentiate, we measured the activation of caspase 3 when 23A2 myoblasts are cultured in DM. We found that caspase 3 is activated with maximal activation of roughly 240% occurring after 3 h in DM (Figure 6). Similar results were obtained when A2:E1A myoblasts were cultured in DM. A minimal (30%) activation of caspase 3 is observed when A2:H-Ras myoblasts are cultured in DM for 3 h (Figure 6). To determine the importance of caspase 3 activation to the apoptosis of 23A2 myoblasts cultured in DM, we used the selective pharmacological inhibitor DEVD-fmk. Since caspase 3 is maximally activated in 23A2 myoblasts cultured in DM for 3 h (Figure 6), we initially chose this condition to examine the effect of DEVD-fmk on caspase 3 activation. We determined that DEVD-fmk blocked caspase 3 activation in a dose-dependent manner (Figure 7A). We then determined the effect of DEVD-fmk on the DNA fragmentation of 23A2 myoblasts after 8 h in DM, a time point at which we had previously determined that most apoptotic myoblasts are still attached to the plate (Figure 2C). We found that DNA fragmentation can be completely blocked with only a 64% reduction in caspase 3 activity (Figure 7A). Furthermore, no apoptotic myoblasts were detected at this time point in the presence of DEVD-fmk (data not shown).
We have used the A2:E1A myoblasts to determine that the inhibition of differentiation does not always result in the inhibition of apoptosis suggesting that the signaling pathways responsible for differentiation can be separated from those responsible for apoptosis. To further establish that point, we chose to monitor the effect of DEVD-fmk on MHC expression in 23A2 myoblasts. MHC, however, can only be readily detected after 24 h in DM, a time point at which all myoblasts that have apoptosed have detached from the plate. Consequently, caspase 3 activity is not detected after 24 h in DM (data not shown). To assess the stability of DEVD-fmk, we cultured myoblasts in DM with DEVD-fmk for 24 h to create ‘aged’ media. We then switched naïve 23A2 myoblasts from GM to this ‘aged’ media and measured the activation of caspase 3 after 3 h, since this is the time point at which maximal caspase 3 activity is observed. We found that the caspase 3 inhibitory activity of ‘aged’ DEVD-fmk was comparable to that of ‘fresh’ DEVD-fmk (Figure 7B). Having assured ourselves of the stability of DEVD-fmk, we next assessed the effect of DEVD-fmk on the differentiation of 23A2 myoblasts and found no effect on the expression of MHC (Figure 7C) or the percentage of myoblasts expressing MHC (Figure 7D). Finally, we assessed the effect of DEVD-fmk on the apoptosis of 23A2 myoblasts cultured in DM for 24 h. After 24 h, DEVD-fmk, although still able to abrogate caspase 3 activity, no longer inhibited DNA fragmentation (Figure 7E) and did not reduce the percentage of apoptotic myoblasts (Figure 7F). This result indicates that abrogating caspase 3 activity only serves to delay the apoptosis of 23A2 myoblasts and eliminates caspase 3 as a target that can be manipulated to block apoptosis without affecting differentiation.
Discussion
In several cell types, differentiation and apoptosis are coordinately regulated.1,2,4,5 While undoubtedly a vital component of development, the linkage of these two processes is obviously detrimental12,13 to the use of myoblast transfer as a gene complementation approach for the treatment of muscular dystrophies8,9,10,11 and certain metabolic deficiencies.36 Finding targets to manipulate that would allow abrogation of apoptosis without affecting differentiation could improve the efficacy of these approaches. We have shown that in skeletal myoblasts both differentiation and the accompanying apoptosis depend on the variables of cell density and time and that these variables are inversely related. For many years it has been accepted that skeletal myoblast differentiation depends on both growth factor depletion and the autocrine secretion of IGFs.18,19 This would explain the dependence of differentiation on the variables of cell density and time and the inverse relationship of these variables. The greater the cell density the faster the growth factor depletion in GM. Likewise, the greater the cell density the less time needed to secrete a sufficient concentration of IGFs in either GM or DM. Obviously, the signaling pathways regulating survival and differentiation are necessarily linked. In fact, survival may be functionally synonymous with differentiation. Whether survival permits differentiation or differentiation permits survival is not clear and in fact, either may be true.
There are at least two scenarios to explain the fact that apoptosis, like differentiation, is also dependent on the variables of cell density and time. The first is simply that, while differentiation is initiated by growth factor depletion, apoptosis may be initiated by trophic factor depletion. Whether or not these factors are the same or distinct remains to be determined. The second is that apoptosis may depend on the secretion of an autocrine factor, which by definition would be a death ligand. It is even possible that both scenarios are responsible for the apoptosis that accompanies skeletal myoblast differentiation.
Constitutive signaling by Ras abrogates the differentiation of skeletal myoblasts.29,30,37,38 We demonstrate in this study that the apoptosis of differentiation-defective A2:H-Ras myoblasts is greatly impaired when compared to parental 23A2 myoblasts cultured under similar conditions. The apoptosis of myoblasts rendered differentiation-defective by expression of E1A (A2:E1A myoblasts), however, is not impaired under these same conditions and indicates that the diminished apoptosis of A2:H-Ras myoblasts is not merely a consequence of their inability to differentiate. If Ras is signaling through only one pathway to inhibit both differentiation and apoptosis, then the signaling pathway(s) leading to differentiation or apoptosis might initially be the same pathway. The fact that the apoptosis of differentiation-defective E1A myoblasts is not diminished suggests that at some point this pathway bifurcates and that E1A is inhibiting only the pathway that leads to differentiation. Alternatively, Ras may be signaling through one pathway to inhibit differentiation and another pathway to inhibit apoptosis. This possibility is currently being investigated with the hope of identifying a pathway downstream from Ras that can be manipulated to inhibit the apoptosis of skeletal myoblasts without affecting their differentiation.
The best characterized signaling pathways downstream from Ras are PI3-kinase/Akt and the Raf/MEK.39 Since signaling through the PI3-kinase pathway has been shown to be critical for normal skeletal myoblast survival/differentiation,20,21,23,24 and Ras signaling abrogates differentiation,29,30,37,38 we focused our attention on the Raf/MEK pathway which has been shown to be anti-apoptotic.33 We have shown that signaling through MEK may play a role in the survival of myoblasts in GM since the abrogation of MEK signaling increases apoptosis in GM to almost the level observed when myoblasts are cultured in DM. The cells that die as a consequence of inhibiting MEK may be the same cells destined to die during the process of differentiation. If this is true, since constitutive MEK signaling does not abrogate differentiation,40 then MEK may be a target which can be manipulated to abrogate apoptosis without affecting differentiation. Experiments to determine this are underway. We have also found that inhibiting constitutive MEK signaling is not sufficient to permit an apoptotic response in A2:H-Ras myoblasts comparable to that of parental 23A2 myoblasts.
With the hope of finding targets that can be manipulated to abrogate apoptosis without affecting the differentiation of skeletal myoblasts, we next examined the activation of caspase 3. We have determined that caspase 3 is activated 2.4-fold when 23A2 myoblasts are cultured in DM. Interestingly, caspase 3 is modestly (30%) activated in parallel cultures of A2:H-Ras myoblasts suggesting that a small amount of caspase 3 activation is tolerated. Selective pharmacological inhibitors of caspase signaling are available and have been used not only to assess the significance of caspase activation in tissue culture but also in animal models of stroke, myocardial ischemia-reperfusion injury, liver disease and traumatic brain injury.26 We have used the selective caspase 3 inhibitor, DEVD-fmk, to determine that activation of caspase 3 plays a role in 23A2 myoblast apoptosis since pharmacological abrogation of caspase 3 activity inhibits apoptosis after 8 h in DM. The fact that total inhibition of DNA fragmentation can be achieved with only a 64% reduction in caspase 3 activity further suggests that a small amount of caspase activity can be tolerated. The inhibition achieved through treatment with DEVD-fmk, however, is not sustainable. Although treatment with DEVD-fmk does not affect differentiation, the fact that it only serves to delay skeletal myoblast apoptosis for a short time eliminates caspase 3 as a target for therapeutic manipulation to improve the efficacy of myoblast transfer. Experiments are underway to further characterize the apoptotic pathway in 23A2 myoblasts and to determine at what point in that pathway Ras is exerting its anti-apoptotic effect.
Materials and Methods
Cells and cell culture
The growth and differentiation properties of 23A2 myoblasts and the 23A2 derivatives expressing G12V:H-Ras (A2:H-Ras myoblasts) or E1A (A2:E1A) have been reported previously.24,25,26 All cells were cultured at low density on gelatin-coated plates and maintained in growth medium (GM), which consists of basal modified Eagle's medium (BME), 10% fetal bovine serum (FBS), and a 1% combination of 10 000 I.U./ml penicillin and 10 000 μg/ml streptomycin (1% P/S). Differentiation was induced by switching cells from GM to differentiation medium (DM), which consists of BME, 1% P/S and 0% FBS. Cells were incubated at 37°C in 5% CO2. PD098059 and DEVD-fmk were each dissolved in DMSO to give a final concentration of 37 mM and 10 μM respectively prior to storage at −20°C. Appropriate volumes of DMSO alone (0.15% v/v) were added to control cultures and never exceeded 0.14% v/v.
Immunoblot analysis
Cells were plated on 35 mm dishes and the next day switched to fresh GM or DM for various times prior to being rinsed in cold 1× phosphate buffered saline (PBS) and then lysed in p21 lysis buffer (20 mM MOPS pH 7.4, 4 mM magnesium chloride, 200 mM sucrose, 0.1 mM EDTA, 0.001% DNAse, 1 M phenyl methyl sulfonyl fluoride, and 50 μg/ml each of aprotinin, pepstatin, and leupeptin) with 1% CHAPS. The protein concentrations of all lysates were determined using Coomassie Protein Assay Reagent from Pierce as per manufacturer's instructions. Following protein determination, lysates (50 μg for MHC detection and 100 μg for phospho-MAPK) were denatured in 5×sample buffer (10% SDS, 50% glycerol, 10% 2-mercaptoethanol, pH 6.8) and electrophoresed through denaturing polyacrylamide gels (8% for MHC detection and 10% for phospho-MAPK). Following SDS polyacrylamide gel electrophoresis (SDS–PAGE), samples were transferred electrophoretically for four amp hours to Hybond-P polyvinylidene difluoride membranes in transfer buffer containing 80% methanol and 1 g/l SDS. Membranes were dried at 37°C for 30 min. Western analysis was performed to detect MHC by incubating the membranes with a mouse monoclonal antibody MF20 that is specific for skeletal myosin heavy chain protein for 1 h followed by an HRP-conjugated mouse polyclonal antibody diluted 1 : 1000 for 1 h.29 Western analysis to detect phospho-MAPK was performed with a polyclonal antibody to the phosphorylated form of MAPK (Santa Cruz) diluted 1 : 500 and incubated with the membrane overnight followed by an HRP-conjugated mouse polyclonal antibody diluted 1 : 1000 and incubated with the membrane for 1 h. To ensure equal protein loading, Western analysis was performed on parallel membranes using an anti-MAPK mouse polyclonal antibody (Upstate Biotechnologies) and an HRP-conjugated anti-mouse polyclonal antibody, each diluted 1 : 1000 and incubated with the membranes for 1 h. After each incubation with antibody and prior to the addition of chemiluminescent substrate, membranes were washed five times in 1×TBS (tris-buffered saline pH 7.4) with 1% NP-40. Membranes were then incubated with SuperSignal West Pico Chemiluminescent Substrate (Pierce) for 60 s and bands were visualized using either Kodak Scientific Imaging Film or a Bio-Rad Fluor-S Multi-imager.
Immunohistochemistry
Cells were plated on gridded 35 mm culture dishes and the next day switched to fresh GM or DM for various times. Attached cells were rinsed in PBS and fixed. Fixed cells were permeabilized with tris-buffered saline/0.1% NP40 and blocked with 2% horse serum in PBS. This was followed by incubation with the MF20 antibody for 60 min, washing with PBS and incubation with a biotinylated goat anti-mouse antibody per manufacturer's instructions (Santa Cruz: ABC staining system). After washing, cells were incubated with HRP-streptavidin and immunoreactivity was visualized using 3,3′-diaminobenzidine (DAB), H2O2 and NiCl2 per manufacturer's instructions. For each condition, at least two fields of not less than 100 cells each were counted independently by two investigators without prior knowledge of the sample identity.
Apoptosis assays
TUNEL assay:
DNA fragmentation is a commonly used marker for apoptotis. Cells were plated on gridded 35 mm culture dishes and the next day switched to fresh GM or DM for various times prior to being rinsed in PBS. In situ DNA fragmentation was visualized using apoTACSTM from R&D Systems per manufacturer's instructions. Floating cells were treated as suspension cells per manufacturer's instructions. Briefly, floating cells were collected by centrifugation at 500×g for 5 min, washed and resuspended in 3.7% buffered formaldehyde for 10 min. After centrifugation, floating cells were resuspended in 80% ethanol and spotted onto new gridded 35 mm culture dishes. After drying for 2 h, cells were immersed in 70% ethanol for 10 min and then allowed to dry. After washing, attached cells were fixed in 3.7% buffered formaldehyde for 10 min, washed, and dehydrated through incubation in increasing concentration of ethanol (70%, 80%, 95% and 100%) for 5 min intervals separated by 10 min intervals of drying. Both dehydrated floating cells and attached cells were rehydrated by immersing for 5 min each in 100%, 95% then 70% ethanol. Cells were then incubated in 1×PBS for 5 min and permeabilized with proteinase K. After washing, cells were incubated for 5 min in terminal deoxynucleotidyl transferase enzyme (TdT) labeling buffer followed by incubation with labeling reaction mix (TDT plus B-dNTPs in labeling buffer) for 1 h in a humidity chamber. Cells were then incubated with TdT stop buffer and washed prior to incubation in detection mix (anti-BrdU antibody and streptavidin-HRP) for 1 h. After washing, cells were incubated with TACS blue label and washed prior to final viewing. For each condition, at least two fields of not less than 100 cells each were counted independently by two investigators without prior knowledge of the sample identity. Total cell numbers were also determined for both attached and corresponding floating cells from parallel plates. The total per cent of apoptotic cells for each plate was calculated as follows:
Cytosolic nucleosome ELISAs:
DNA fragmentation and nuclear membrane disruption, as monitored by the presence of cytosolic nucleosomes, was also used as a marker for apoptosis. Cytosolic nucleosomes were measured using the Cell Death Detection ELISA Plus Kit (Roche Diagnostics) per manufacturer's instructions. Cells were plated on 35 mm dishes and the next day switched to fresh GM or DM for various times. Attached cells were rinsed in PBS and then lysed by incubation in 300 μl cell lysis buffer from the kit on a rocker for 30 min at room temperature. Samples were diluted fourfold and 20 μl of each sample was transferred to a 96-well, flat-bottomed, streptavidin-coated microtiter plate. Seventy-two microliters of 1× incubation buffer from the kit, and 4 μl each of biotin conjugated anti-histone antibody and peroxidase conjugated anti-DNA antibody was added to the lysate in the microtiter plate and incubated at 4°C overnight. Following three washes with 300 μl of incubation buffer, the presence of cytosolic nucleosomes was measured by adding 100 μl of the substrate, ABTS. This was incubated in the microtiter plates for 5–20 min at room temperature and then the color reaction was quantitated on a spectrophotometer at 405 nm. Experiments were performed within the linear range of the assay. Attached cells from parallel plates were counted and absorbance was normalized to cell number. A background (no lysate) measurement was taken and subtracted for each experiment.
Phosphatidylserine asymmetry:
Another commonly used marker for apoptosis is loss of membrane phospholipid asymmetry. Normally, phosphatidylserine (PS) is located in the inner leaflet but during apoptosis PS appears in the outer leaflet. Labeled annexin V binds to PS. Propidium iodide is used to eliminate cells that have been labeled with annexin V due to membrane rupture rather than loss of membrane phospholipid assymetry. Equal cell numbers were plated and the next day switched to DM for 12 h. Cells were trypsinized, pelleted and washed twice in phosphate-buffered saline (PBS). Samples were taken to the Cleveland Clinic Foundation Flow Cytometry Core for labeling and analysis. Cells were labeled with fluorscein-conjugated annexin V using an Apoptosis Detection Kit from R&D Systems per manufacturer's instructions. Briefly, washed cells were resuspended in binding buffer at a concentration of 1×106 cells/ml. To 100 μl of this, 10 μl of fluorscein-conjugated annexin V and 10 μl of propidium iodide reagent were added. After 15 min at room temperature, 400 μl of binding buffer was added and samples were analyzed immediately.
Caspase 3 assays
Caspase 3 colorimetric assays were performed using the Caspase 3 Colorimetric Assay Kit from R&D Systems per manufacturer's instructions. Cells were plated and the next day switched to fresh GM or DM for various times prior to being rinsed in PBS. Attached cells were lysed in 50 μl of lysis buffer. Following sedimentation, 50 μl of lysate was incubated with 50 μl of 2× reaction buffer supplemented with 0.5 μl DTT and 5 μl of the caspase 3 colorimetric substrate, DEVD-pNA. Following 1–2 h of incubation at 37°C, caspase-3 protease activity was measured on a spectrophotometer at 405 nm. Experiments were performed within the linear range of the assay and absorbance was normalized by the protein concentration of each lysate as determined using Coomassie Protein Assay Reagent from Pierce. Fold increase in caspase 3 activity in DM was calculated relative to the absorbance value obtained from the lysate of cells incubated in fresh GM for 1 h.
Abbreviations
- MRFs:
-
muscle regulatory transcription factors
- GM:
-
growth medium
- DM:
-
differentiation medium
- MHC:
-
myosin heavy chain
- BME:
-
basal modified Eagle's medium
- FBS:
-
fetal bovine serum
- TdT:
-
terminal deoxynucleotidyl transferase
- PS:
-
phosphatidyl serine
- PBS:
-
phosphate-buffered saline
References
Ellis RE, Yuan JY, Horvitz HR . 1991 Mechanisms and functions of cell-death Annu. Rev. Cell Biol. 7: 663–698
Raff MC . 1992 Social controls on cell-survival and cell-death Nature 356: 397–400
Thompson CB . 1995 Apoptosis in the pathogenesis and treatment of disease Science 267: 1456–1462
Fidzianska A, Goebel HH . 1991 Human ontogenesis 3. Cell death in fetal muscle Acta Neuropathol 81: 572–577
Miller JB, Stockdale FE . 1986 Developmental regulation of the multiple myogenic cell lineages of the avian embryo J. Cell Biol. 103: 2197–2208
Sandri M, Cantini M, Massimino ML, Geromel V, Arslan P . 1996 Myoblasts and myotubes in primary cultures deprived of growth factors undergo apoptosis Basic Appl. Myol. 6: 257–260
Wang J, Walsh K . 1996 Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation Science 273: 359–361
Tews DS, Goebel HH . 1997 DNA-fragmentation and expression of apoptosis-related proteins in muscular dystrophies Neuropathol. Appl. Neurobiol. 23: 331–338
Tidball JG, Albrecht DE, Lokensgard BE, Spencer MJ . 1995 Apoptosis precedes necrosis of dystrophin-deficient muscle J. Cell Sci. 108: 2197–2204
Fidzianska A, Goebel HH, Warlo I . 1990 Acute infantile spinal muscular atrophy. Muscle apoptosis as a proposed pathogenetic mechanism Brain 113: 433–445
Tews DS, Goebel HH . 1996 DNA fragmentation and bcl-2 expression in infantile spinal muscular atrophy Neuromusc. Disord. 6: 265–273
Skuk D, Tremblay JP . 2000 Progress in myoblast transplantation: A potential treatment of dystrophies Microsc. Res. Tech. 48: 213–222
Hartigan-O'Conner D, Chamberlain JS . 2000 Developments in gene therapy for muscular dystrophy Microsc. Res. Tech. 48: 223–238
Gussoni E, Blau HM, Kunkel LM . 1997 The fate of individual myoblasts after transplantation into muscles of DMD patients Nature Medicine 3: 970–977
Partridge T, Lu QL, Morris G, Hoffman E . 1998 Is myoblast transplantation effective? Nature Med. 4: 1208–1209
Pagel CN, Morgan JE . 1995 Myoblast transfer and gene therapy in muscular dystrophies Microsc. Res. Tech. 30: 469–479
Perry RLS, Rudnicki MA . 2000 Molecular mechanisms regulating myogenic determination and differentiation Frontiers Biosci. 5: 750–767
Florini JR, Ewton DZ, Magri KA . 1991 Hormones, growth factors, and myogenic differentiation Annu. Rev. Physiol. 53: 201–216
Florini JR, Magri KA, Ewton DZ, James P, Grindstaff K, Rotwein P . 1991 ‘‘Spontaneous’’ differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin-like growth factor J. Biol. Chem. 266: 15917–15923
Coolican S, Samuel D, Ewton D, McWade F, Florini JR . 1997 The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways J. Biol. Chem. 272: 6653–6662
Jiang BH, Aoki M, Zheng JZ, Li J, Vogt PK . 1999 Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B Proc. Natl. Acad. Sci. U.S.A. 96: 2077–2081
Weyman CM, Wolfman A . 1998 Mitogen-activated protein kinase kinase (MEK) activity is required for inhibition of skeletal muscle differentiation by insulin-like growth factor-1 or fibroblast growth factor-2 Endocrinology 139: 1794–1800
Fujio Y, Guo K, Mano T, Mitsuuchi Y, Testa JR, Walsh K . 1999 Cell cycle withdrawal promotes myogenic induction of Akt, a positive modulator of myocyte survival Mol. Cell. Biol. 19: 5073–5082
Lawlor MA, Rotwein P . 2000 Insulin-like growth factor-mediated cell survival: central roles for Akt and cyclin-dependent kinase inhibitor p21 Mol. Cell. Biol. 20: 8983–8995
Salvesen G, Dixit VM . 1997 Caspases: Intracellular signaling by proteolysis Cell 91: 443–446
Thornberry N, Lazebnik Y . 1998 Caspases: Enemies within Science 281: 1312–1316
Rodriguez J, Lazebnik Y . 1999 Caspase-9 and APAF-1 form an active holoenzyme Genes Dev. 13: 3179–3184
Green DR . 1998 Apoptotic pathways: The roads to ruin Cell 94: 695–698
Weyman CM, Ramocki MB, Taparowsky EJ, Wolfman A . 1997 Distinct signaling pathways regulate transformation and inhibition of skeletal muscle differentiation by oncogenic Ras Oncogene 14: 697–704
Konieczny SF, Drobes BL, Menke SL, Taparowsky EJ . 1989 Inhibition of myogenic differentiation by the H-ras oncogene is associated with the downregulation of the MyoD1 gene Oncogene 4: 473–481
Enkemann SA, Konieczny SF, Taparowsky EJ . 1990 Adenovirus 5 E1A represses muscle-specific enhancers and inhibits expression of the myogenic regulatory factor genes, MyoD1 and myogenin Cell Growth Differ. 1: 375–382
Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC . 1998 Regulation of cell death protease caspase 9 by phosphorylation Science 282: 1318–1321
Bonni A, Brunet A, West A, Sandeep RA, Takasu MA, Greenberg ME . 1999 Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms Science 286: 1358–1362
Brown TL, Patil S, Cianci CD, Morrow JS, Howe PH . 1999 Transforming growth factor beta induces caspase 3-independent cleavage of alphaII-spectrin (alpha-fodrin) coincident with apoptosis J. Biol. Chem. 274: 23256–23262
Miyashita T, Nagao K, Krajewski S, Salvesen G, Reed JC, Inoue T, Yamada M . 1998 Investigation of glucocorticoid-induced apoptotic pathway:processing of caspase-6 but not caspase-3 Cell Death Differ. 5: 1034–1041
Moisset PA, Bonham L, Skuk D, Koeberl D, Brusse V, Goulet M, Roy B, Asselin I, Miller AD, Tremblay JP . 2000 Systemic production of human granulocyte colony stimulating factor in nonhuman primates by transplantation of genetically modified myoblasts Hum. Gene Ther. 11: 1277–1288
Olson E . 1992 Interplay between proliferation and differentiation Dev. Biol. 154: 261–272
Weyman CM, Wolfman A . 1997 Oncogenic Ras-induced secretion of a novel inhibitor of skeletal myoblast differentiation Oncogene 15: 2521–2528
Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ . 1998 Increasing complexity of Ras signaling Oncogene 17: 1395–1413
Ramocki MB, Johnson SE, White MA, Ashendel CL, Koniescny SF, Taparowsky EJ . 1997 Signaling through mitogen-activated protein kinase and Rac/Rho does not duplicate the effects of activated Ras on skeletal myogenesis Mol. Cell. Biol. 17: 3547–3555
Acknowledgements
This work was partially supported by NIH/NCI grant RO1CA84212-01 awarded to CM Weyman and by start-up funds provided by Cleveland State University and the Cleveland Clinic Foundation.
Author information
Authors and Affiliations
Corresponding author
Additional information
Edited by DR Green
Rights and permissions
About this article
Cite this article
Dee, K., Freer, M., Mei, Y. et al. Apoptosis coincident with the differentiation of skeletal myoblasts is delayed by caspase 3 inhibition and abrogated by MEK-independent constitutive Ras signaling. Cell Death Differ 9, 209–218 (2002). https://doi.org/10.1038/sj.cdd.4400930
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4400930
Keywords
This article is cited by
-
The muscle regulatory transcription factor MyoD participates with p53 to directly increase the expression of the pro-apoptotic Bcl2 family member PUMA
Apoptosis (2017)
-
Cell death, clearance and immunity in the skeletal muscle
Cell Death & Differentiation (2016)
-
Dual Oxidase Maturation factor 1 (DUOXA1) overexpression increases reactive oxygen species production and inhibits murine muscle satellite cell differentiation
Cell Communication and Signaling (2014)
-
Increased expression of the pro-apoptotic Bcl2 family member PUMA and apoptosis by the muscle regulatory transcription factor MyoD in response to a variety of stimuli
Apoptosis (2010)
-
Atrophy and programmed cell death of skeletal muscle
Cell Death & Differentiation (2008)